September 18, 2025

Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC

Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB NSCLC, based on the prim...

The ASCO Post

September 18, 2025

Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types

Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, ac...

The ASCO Post

September 18, 2025

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

“Maintaining quality of life during and after treatment is vital to long-term success, and these results show that perioperative nivolumab supports both survival and patient well-being,” said experts ...

The ASCO Post

September 18, 2025

Policy Review: HRQoL Data in Clinical Trials for Advanced Cancer

A new policy review emphasizes the critical role of health-related quality of life (HRQoL) data in the evaluation of treatments for people with advanced cancer, highlighting the importance of having s...

The ASCO Post

September 18, 2025

Study Finds Insufficient Evidence Demonstrating Clinical Benefit of Multicancer Detection Tests

Although the early detection of cancer using blood-based multicancer detection (MCD) tests is a promising new technology, currently, no completed controlled studies report benefits of screening with t...

The ASCO Post

September 18, 2025

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cel...

The ASCO Post

September 17, 2025

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could...

The ASCO Post

September 16, 2025

Study Finds High-Risk Prescriptions Drive Frailty, Hospitalization, and Mortality in Older Adults With Cancer

Using the Geriatric Oncology Potentially Inappropriate Medications scale (GO-PIMs), researchers found that older adults are likely to be taking a number of potentially inappropriate or high-risk medic...

The ASCO Post

September 15, 2025

Is Cure Finally Achievable in Multiple Myeloma?

After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills ...

The ASCO Post